Kinase Inhibitor

Cytochrome P450 3A4 Inhibitors

P-Glycoprotein Inhibitors

Cytochrome P450 3A4 Inducers

Organic Cation Transporter 2 Inhibitors

Fibroblast Growth Factor Receptor Inhibitors

Carcinoma, Transitional Cell

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Erdafitinib, the active ingredient in BALVERSA, is a kinase inhibitor. The chemical name is N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine. Erdafitinib is a yellow powder. It is practically insoluble, or insoluble to freely soluble in organic solvents, and slightly soluble to practically insoluble, or insoluble in aqueous media over a wide range of pH values. The molecular formula is C   <span class="Sub">25</span>H   <span class="Sub">30</span>N   <span class="Sub">6</span>O   <span class="Sub">2</span>and molecular weight is 446.56. </p><p>Chemical structure of erdafitinib is as follows:</p><div class="Figure"><img alt="Chemical Structure" src="balversa-01.jpg"/></div><p>BALVERSA   <span class="Sup">®</span>(erdafitinib) tablets are supplied as 3 mg, 4 mg or 5 mg film-coated tablets for oral administration and contains the following inactive ingredients: </p><p>Tablet Core: Croscarmellose sodium, Magnesium stearate (from vegetable source), Mannitol, Meglumine, and Microcrystalline Cellulose.</p><p>Film Coating: (Opadry amb II): Glycerol monocaprylocaprate Type I, Polyvinyl alcohol-partially hydrolyzed, Sodium lauryl sulfate, Talc, Titanium dioxide, Iron oxide yellow, Iron oxide red (for the orange and brown tablets only), Ferrosoferric oxide/iron oxide black (for the brown tablets only).</p></section>

BALVERSA

erdafitinib

erdafitinib 3 MG Oral Tablet

Balversa

erdafitinib 3 MG Oral Tablet [Balversa]

erdafitinib 4 MG Oral Tablet

erdafitinib 4 MG Oral Tablet [Balversa]

erdafitinib 5 MG Oral Tablet

erdafitinib 5 MG Oral Tablet [Balversa]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

How To Order Balversa 

How to Order Balversa - ASD Healthcare

CVS Specialty Referral Form

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Formulary Exception Letter 

Prior Authorization Considerations Checklist 

Enroll in Patient Savings Program 

Janssen Patient Assistance Program Application - Check Eligibiligy 

FGFR Testing Lab Finder 

Other HCP Resources: Access 

About Balversa 

Side Effects

Taking Balversa 

Patient Resources 

Instructions For Use: Bladder Cancer 

Balversa Managing Side Effects Brochure 